Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxorubicin
Drug ID BADD_D00723
Description Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.
Indications and Usage Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Marketing Status approved; investigational
ATC Code L01DB01
DrugBank ID DB00997
KEGG ID D03899
MeSH ID D004317
PubChem ID 31703
TTD Drug ID D07VLY
NDC Product Code 12543-3209; 70121-1218
UNII 80168379AG
Synonyms Doxorubicin | Farmiblastina | Ribodoxo | Rubex | Adriamycin | Adriblastin | Adriblastine | Adriblastina | Adriablastine | Adriablastin | Adrimedac | DOXO-cell | DOXO cell | Urokit Doxo-cell | Urokit Doxo cell | Doxolem | Doxorubicin Hexal | Doxorubicin Hydrochloride | Hydrochloride, Doxorubicin | Doxorubicin NC | Doxorubicina Ferrer Farm | Doxorubicina Funk | Doxorubicina Tedec | Doxorubicine Baxter | Doxotec | Myocet | Onkodox
Chemical Information
Molecular Formula C27H29NO11
CAS Registry Number 23214-92-8
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Spondylolisthesis12.04.04.008; 15.10.04.0040.000112%Not Available
Ovarian cancer recurrent16.12.04.005; 21.11.01.0140.000224%Not Available
Oncologic complication16.32.03.0250.000112%Not Available
Acute lung injury22.01.03.0100.000168%Not Available
Psychological trauma19.01.02.0170.005115%Not Available
Systolic dysfunction02.04.02.0350.000392%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000168%Not Available
Soft tissue sarcoma16.33.01.003; 15.09.03.0210.000392%Not Available
Adult failure to thrive14.03.02.020; 08.01.01.014; 19.15.02.0090.000168%Not Available
End stage renal disease20.01.03.0190.000112%Not Available
Administration site extravasation12.07.04.019; 08.02.04.0190.000638%Not Available
Administration site injury08.02.04.023; 12.07.04.0230.000168%Not Available
Biliary-bronchial fistula12.02.03.025; 22.03.02.012; 09.02.03.0060.000168%Not Available
Cardiac dysfunction02.11.01.0040.000448%Not Available
Dilated cardiomyopathy02.04.01.0170.001119%Not Available
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.000660%Not Available
Granulomatous pneumonitis22.01.01.0260.000112%Not Available
Hypersensitivity pneumonitis22.01.01.027; 10.01.03.0560.000112%Not Available
Left ventricular dilatation02.04.02.044--Not Available
Leiomyosarcoma recurrent16.33.07.004; 15.09.03.0260.000112%Not Available
Mucosal disorder08.01.06.029--Not Available
Myelosuppression01.03.03.0150.000392%Not Available
Myocardial injury02.04.02.0460.000224%Not Available
Right ventricular dilatation02.04.02.0500.000112%Not Available
Right ventricular enlargement02.04.02.0510.000112%Not Available
Sarcoma metastatic16.33.01.005; 15.09.03.0350.000168%Not Available
Squamous cell carcinoma of head and neck16.16.01.0240.000280%Not Available
Taste disorder17.02.07.029; 07.14.03.0040.000168%Not Available
Therapy partial responder08.06.01.0640.000392%Not Available
Toxic erythema of chemotherapy23.03.05.013; 17.02.07.0300.000168%Not Available
The 24th Page    First    Pre   24 25    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene